Skip to main content
Caplight Logo









Shenzhen TargetRx

Shenzhen TargetRx

Private
ShenzhenHealthcare & Life Scienceshttps://www.tjrbiosciences.com/

Last Round

Series C

Jan 23, 2025

Total Funding Raised

$106M

Company Overview

Shenzhen TargetRx is a clinical-stage pharmaceutical company that specializes in the research and development of targeted small molecule anti-cancer therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaltargeted therapykinase inhibitoroncologyprecision medicinedrug discoveryclinical trialssmall-molecule drugsdrug resistancebiotechpharma licensingALK inhibitorROS1 inhibitorBCR-ABL inhibitordrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shenzhen TargetRx Comparables

Compare Shenzhen TargetRx with similar companies based on industry and business-model similarity.

Shenzhen TargetRx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nuvalent, Inc.
78%
Theseus Pharmaceuticals
78%
Ascentage Pharma Group International
76%

Shenzhen TargetRx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJan 23, 2025
StrategicSep 7, 2024
Series BJul 5, 2022
StrategicSep 17, 2020
Series AApr 30, 2020
Pre Seed
Jul 25, 2018

Shenzhen TargetRx Investors

Notable investors and investment history

Shenzhen TargetRx investors
InvestorRounds
Oriental Fortune CapitalSeries B, Series A
CDH BaifuSeries B
CCB InternationalSeries B
Shenzhen Capital GroupSeries B, Pre Seed, Series A
Hongtai FundStrategic

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2025

    Monthly visitors grew 283% MoM, from 313 to 1.2K.

  • Jan 23, 2025

    $50M round completed.

Shenzhen TargetRx Filings

Explore SEC and related filing metadata, where available.

Shenzhen TargetRx filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Shenzhen TargetRx's valuation, stock price, and market status.

Is Shenzhen TargetRx a public or private company?

Shenzhen TargetRx is a private company.

What is the current stock price of Shenzhen TargetRx?

Shenzhen TargetRx is a private company with no public stock price. No recent secondary market data is available.

How much is Shenzhen TargetRx worth (valuation)?

Valuation information for Shenzhen TargetRx is not publicly available.

Can I buy Shenzhen TargetRx stock?

Shenzhen TargetRx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Shenzhen TargetRx's last funding round?

Shenzhen TargetRx's most recent funding round was Series C on January 23, 2025.

Who are the main investors in Shenzhen TargetRx?

Key investors in Shenzhen TargetRx include CDH Baifu.

Will Shenzhen TargetRx IPO soon?

No public IPO plans have been announced for Shenzhen TargetRx.

How can I track Shenzhen TargetRx secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Shenzhen TargetRx's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShenzhen
Employee Range11
Year Founded2014
Last FundingJan 23, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?